Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI076205-01A1
Agency Tracking Number: AI076205
Amount: $147,459.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
DUNS: 143606742
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 () -
Business Contact
Phone: (508) 831-6383
Research Institution
DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial c ell monolayers. The goals of this Phase I proposal are to evaluate two, in vivo models of vascular leakage, selecting one model for further in vivo analysis of diphtheria toxin mutants generated by AGI. Successful completion of these studies will result in the determination of modified diphtheria toxin toxophores suitable for protein fusion toxin development and testing in disease-specific, in vivo models. Vascular leakage in humans is a common side effect of fusion toxin therapy and may be inhibiting the d evelopment of this class of therapeutic agent. Advances in reduction of vascular leakage could enhance the therapeutic index of these drugs and make them available to a wider population of patients. Currently there is only one FDA approved drug in this cla ss, ONTAK, which is used to treat persistent or recurrent cutaneous T-cell lymphoma. Sales of this drug range between 30 and 40M annually. PUBLIC HEALTH RELEVANCE: This project seeks to develop modified diphtheria toxin interleukin-2 molecules with reduc ed side effect profiles. In excess of 30% of all patients that currently receive DAB389IL-2, or ONTAK(r), experience vascular leak syndrome. The molecules being developed and tested in these studies will potentially provide a path for the development of th e next generation of ONTAK(r) that may be more appropriate for a wider patient population afflicted with a broader range of diseases.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government